Skip to main content

Vericel Corp

corporate_fare Company Profile

Vericel Corp

VCEL·NASDAQ·Life Sciences·CIK 0000887359

Vericel Corporation provides advanced therapies for sports medicine and severe burn care markets. The company offers a portfolio of cell therapy and specialty biologic products. Vericel markets two U.S. Food and Drug Administration ("FDA") approved autologous cell therapy products and one FDA-approved specialty biologic product in the U.S. MACI® is an autologous cellularized scaffold product for repairing symptomatic, single or multiple full-thickness cartilage defects of the knee, with or without bone involvement, in adults. MACI's FDA-approved labeling initially provided for treatment through an open surgical procedure. In August 2024, the FDA approved a supplemental Biologics License Application ("sBLA") expanding the MACI indication to include instructions for arthroscopic delivery. MACI Arthro® allows surgeons to evaluate and prepare the cartilage defect site and deliver the MACI implant through small incisions using custom-designed arthroscopic instruments developed by the Company ("MACI Arthro instruments"). MACI Arthro became commercially available in the U.S. during the third quarter of 2024, and the Company began selling MACI Arthro instruments at that time. Epicel® is a permanent skin replacement Humanitarian Use Device ("HUD") for treating adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of a patient's total body surface area ("TBSA"). Vericel also holds an exclusive license from MediWound Ltd. for the North American rights to NexoBrid® (anacaulase-bcdb), a topically-administered biological orphan product containing proteolytic enzymes, indicated for the removal of eschar in adult and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.

Vericel Corp (NASDAQ:VCEL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for VCEL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for VCEL spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Vericel 10-Q Confirms Q3 Net Income of $14.2M on $85.4M Revenue, $235.6M in Cash and Investments
  • Vericel Beats on Q3, Raises 2026 Revenue Guidance to $344-$346M
  • Vericel Posts $14.2M Q3 Net Income, Swinging Sharply Higher
  • Vericel Turns Profitable in Q2, Authorizes $200M Buyback, and Locks in BARDA Pact
  • Vericel lifts 2026 guidance on 22% revenue growth and launches $200M buyback

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$276.26M
Net Income
$16.52M
Diluted EPS
$0.32
Op. Cash Flow
$51.91M
Free Cash Flow
$24.75M
Gross Profit
$205.6M
Operating Income
$11.04M
Cash & Equivalents
$100.09M
Debt / Equity
0.00×
Net Margin
6.0%
Shares Outstanding
50.62M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-012013

Short Interest & Short Volume

9.83 days to cover

FINRA reported short interest of 5,364,126 shares in VCEL as of the October 30, 2026 settlement, a 2.4% increase from the prior period — about 9.8 days to cover at its recent average daily volume. On November 19, 2026, 46.0% of VCEL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,364,126 shares as of October 30, 2026
Change vs prior period▲ 2.4%
Days to cover9.83 at avg daily volume of 545,843
Daily short volume (FINRA facilities)46.0% of 334,890 shares on November 19, 2026
5-day average short volume37.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with V →
$57.58 -1.17% today
52-week range · as of 2026-11-05 $28.95 – $57.58
Market cap
$2.94B
Volume
331.9K (0.4× avg)
3-mo avg 808.1K
Live data · 2026-11-20 20:42 UTC · Market open

show_chartPrice Chart

Loading chart...

feed VCEL - Latest Insights

VCEL
Nov 05, 2026, 8:56 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $49.00
Real-time Price: $57.58 info
Change: +$8.58 (+18%) info
Market Cap: $2.937B info
VCEL
Nov 05, 2026, 8:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $48.89
Real-time Price: $57.58 info
Change: +$8.69 (+18%) info
Market Cap: $2.937B info
VCEL
Nov 05, 2026, 7:55 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $45.48
Real-time Price: $57.58 info
Change: +$12.10 (+27%) info
Market Cap: $2.937B info
VCEL
Jul 30, 2026, 8:49 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $48.59
Real-time Price: $57.58 info
Change: +$8.99 (+19%) info
Market Cap: $2.937B info
VCEL
Jul 30, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $48.59
Real-time Price: $57.58 info
Change: +$8.99 (+19%) info
Market Cap: $2.937B info
VCEL
Jul 30, 2026, 7:55 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $48.59
Real-time Price: $57.58 info
Change: +$8.99 (+19%) info
Market Cap: $2.937B info
VCEL
May 07, 2026, 8:54 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $39.40
Real-time Price: $57.58 info
Change: +$18.18 (+46%) info
Market Cap: $2.937B info
VCEL
May 07, 2026, 7:57 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $38.33
Real-time Price: $57.58 info
Change: +$19.25 (+50%) info
Market Cap: $2.937B info
VCEL
May 07, 2026, 7:45 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $37.50
Real-time Price: $57.58 info
Change: +$20.08 (+54%) info
Market Cap: $2.937B info
VCEL
Apr 02, 2026, 2:43 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $34.49
Real-time Price: $57.58 info
Change: +$23.10 (+67%) info
Market Cap: $2.937B info
VCEL
Mar 04, 2026, 8:04 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $34.50
Real-time Price: $57.58 info
Change: +$23.08 (+67%) info
Market Cap: $2.937B info
VCEL
Feb 26, 2026, 9:00 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $37.26
Real-time Price: $57.58 info
Change: +$20.32 (+55%) info
Market Cap: $2.937B info
VCEL
Feb 26, 2026, 8:02 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $37.15
Real-time Price: $57.58 info
Change: +$20.43 (+55%) info
Market Cap: $2.937B info
VCEL
Jan 13, 2026, 9:11 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $37.00
Real-time Price: $57.58 info
Change: +$20.58 (+56%) info
Market Cap: $2.937B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets